Christopher T. Harbison
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 34
- Cancer Immunotherapy and Biomarkers 25
- Colorectal Cancer Treatments and Studies 9
- Lung Cancer Research Studies 5
- Peptidase Inhibition and Analysis 4
- Pancreatic and Hepatic Oncology Research 4
-
- Lung Cancer Treatments and Mutations 11
- Co-authors
- Richard A. Young (5 shared papers)Tong Ihn Lee (3 shared papers)Julia Zeitlinger (4 shared papers)Nancy M. Hannett (4 shared papers)David K. Gifford (3 shared papers)Eric S. Lander (2 shared papers)Ezra G. Jennings (2 shared papers)Dmitry Pokholok (2 shared papers)
- Journals
- Annals of Oncology (9 papers)Journal of Clinical Oncology (6 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)Cell (3 papers)European Journal of Cancer (3 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Christopher T. Harbison
48 papers receiving 31.7k citations
Christopher T. Harbison's Hit Papers
Peers
Comparison fields: 5 of 165
- Oncology 18.5k
- Immunology 5.8k
- Pulmonary and Respiratory Medicine 7.6k
- Cancer Research 2.4k
- Molecular Biology 8.9k
Countries citing papers authored by Christopher T. Harbison
This map shows the geographic impact of Christopher T. Harbison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher T. Harbison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher T. Harbison more than expected).
Fields of papers citing papers by Christopher T. Harbison
This network shows the impact of papers produced by Christopher T. Harbison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher T. Harbison. The network helps show where Christopher T. Harbison may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher T. Harbison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 8004 |
| 2 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 7150 |
| 3 | Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma Hit paper breakdown → | 2014 | 3649 |
| 4 | Transcriptional Regulatory Networks in Saccharomyces cerevisiae Hit paper breakdown → | 2002 | 2293 |
| 5 | Transcriptional regulatory code of a eukaryotic genome Hit paper breakdown → | 2004 | 1661 |
| 6 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Hit paper breakdown → | 2015 | 1240 |
| 7 | Remodeling of Yeast Genome Expression in Response to Environmental Changes Hit paper breakdown → | 2001 | 1133 |
| 8 | Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast Hit paper breakdown → | 2005 | 1102 |
| 9 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 1067 |
| 10 | Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Hit paper breakdown → | 2007 | 991 |
| 11 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer Hit paper breakdown → | 2018 | 518 |
| 12 | 2001 | 509 | |
| 13 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 484 |
| 14 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 439 |
| 15 | Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 Hit paper breakdown → | 2017 | 411 |
| 16 | 2016 | 386 | |
| 17 | 2010 | 230 | |
| 18 | 2003 | 189 | |
| 19 | 2007 | 153 | |
| 20 | 2017 | 134 |
About Christopher T. Harbison
Christopher T. Harbison is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology, having authored 48 papers that have together received 32.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (9 papers), Fungal and yeast genetics research (6 papers), Lung Cancer Research Studies (5 papers), Genomics and Chromatin Dynamics (4 papers), Peptidase Inhibition and Analysis (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). The work is most often cited by research in Oncology (18.5k citations), Immunology (5.8k citations), Pulmonary and Respiratory Medicine (7.6k citations), Cancer Research (2.4k citations) and Molecular Biology (8.9k citations). Christopher T. Harbison has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Richard A. Young, Tong Ihn Lee, Julia Zeitlinger, Nancy M. Hannett, David K. Gifford, Eric S. Lander, Ezra G. Jennings, Dmitry Pokholok, Nicola J. Rinaldi and Bing Ren. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cell and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.